Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 120,000 shares at $70.19 ($8.1M) on 2021-12-15, disclosed to the SEC on 2021-12-17.
Seasonal sale ($8.1M) by Chief Executive Officer — this insider has traded ARWR in December in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.28 | 25,857 | $1.7M | 21.1% |
| 2 | $66.28 | 25,857 | $1.7M | 21.1% |
| 3 | $67.19 | 14,857 | $998K | 12.3% |
| 4 | $67.19 | 14,857 | $998K | 12.3% |
| 5 | $68.20 | 3,074 | $210K | 2.6% |
| 6 | $68.20 | 3,074 |
| $210K |
| 2.6% |
| 7 | $69.52 | 9,223 | $641K | 7.9% |
| 8 | $69.52 | 9,223 | $641K | 7.9% |
| 9 | $70.19 | 6,989 | $491K | 6.1% |
| 10 | $70.19 | 6,989 | $491K | 6.1% |
| Total | $67.56 avg | 120,000 | $8.1M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |